JP2007514691A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007514691A5 JP2007514691A5 JP2006544348A JP2006544348A JP2007514691A5 JP 2007514691 A5 JP2007514691 A5 JP 2007514691A5 JP 2006544348 A JP2006544348 A JP 2006544348A JP 2006544348 A JP2006544348 A JP 2006544348A JP 2007514691 A5 JP2007514691 A5 JP 2007514691A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- hydrogen
- solvate
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000006239 protecting group Chemical group 0.000 claims 5
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 239000000048 adrenergic agonist Substances 0.000 claims 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- CQRYARSYNCAZFO-UHFFFAOYSA-N o-hydroxybenzyl alcohol Natural products OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 claims 1
- 150000008052 alkyl sulfonates Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- -1 haloalkyl sulfonate Chemical compound 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0329182.0A GB0329182D0 (en) | 2003-12-17 | 2003-12-17 | Chemical compounds |
| PCT/EP2004/014381 WO2005058867A1 (en) | 2003-12-17 | 2004-12-15 | Benzothiophene-and thiochromene containing phenethanolamine derivatives for the treatment of respiratory disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007514691A JP2007514691A (ja) | 2007-06-07 |
| JP2007514691A5 true JP2007514691A5 (enExample) | 2007-12-27 |
Family
ID=30471187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006544348A Pending JP2007514691A (ja) | 2003-12-17 | 2004-12-15 | 呼吸器疾患を治療するためのベンゾチオフェンおよびチオクロメン含有フェネタノールアミン誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7294650B2 (enExample) |
| EP (1) | EP1730133A1 (enExample) |
| JP (1) | JP2007514691A (enExample) |
| GB (1) | GB0329182D0 (enExample) |
| WO (1) | WO2005058867A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| RU2442771C2 (ru) | 2005-08-08 | 2012-02-20 | Арджента Дискавери Лтд | Производные бицикло[2,2,1]гепт-7-иламина и их применения |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| PE20080361A1 (es) | 2006-04-21 | 2008-06-03 | Novartis Ag | Compuestos derivados de purina como activadores del receptor de adenosina a2a |
| KR20100113557A (ko) | 2008-01-11 | 2010-10-21 | 노파르티스 아게 | 키나제 억제제로서의 피리미딘 |
| US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| EP2379507B1 (en) | 2008-12-30 | 2013-10-16 | Pulmagen Therapeutics (Inflammation) Limited | Sulfonamide compounds for the treatment of respiratory disorders |
| WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
| GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
| GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
| GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
| WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
| GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| KR20140014184A (ko) | 2011-02-25 | 2014-02-05 | 아이알엠 엘엘씨 | Trk 억제제로서의 화합물 및 조성물 |
| US20150038719A1 (en) | 2012-03-14 | 2015-02-05 | Ltt Bio-Pharma Co., Ltd. | Agent for Ameliorating Chronic Obstructive Pulmonary Disease |
| KR101627841B1 (ko) * | 2015-05-27 | 2016-06-07 | 다이아텍코리아 주식회사 | 싸이오크로멘 타입 화합물 및 그 용도 |
| WO2018033493A1 (en) * | 2016-08-16 | 2018-02-22 | Basf Se | High refractive index liquids based on meta-substituted s-alkyl thioethers |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2918408A (en) * | 1957-04-08 | 1959-12-22 | Lakeside Lab Inc | Anti-spasmodic compositions specific for treating spasm of the colon |
| BR8007911A (pt) * | 1979-12-06 | 1981-06-16 | Glaxo Group Ltd | Inalador aperfeicoado |
| CY1308A (en) | 1979-12-06 | 1985-12-06 | Glaxo Group Ltd | Device for dispensing medicaments |
| ATE23272T1 (de) | 1981-07-08 | 1986-11-15 | Draco Ab | Pulverinhalator. |
| ES286422Y (es) | 1982-10-08 | 1986-09-16 | Glaxo Group Limited | Dispositivo para administrar medicamentos a pacientes |
| GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
| US4778054A (en) * | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| GB8310477D0 (en) * | 1983-04-18 | 1983-05-25 | Glaxo Group Ltd | Chemical compounds |
| ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| AU581887B2 (en) | 1984-04-17 | 1989-03-09 | Glaxo Group Limited | Ethanolamine compounds |
| CH665632A5 (fr) | 1984-07-13 | 1988-05-31 | Glaxo Group Ltd | Composes d'aminophenol. |
| GB8426191D0 (en) | 1984-10-17 | 1984-11-21 | Glaxo Holdings Ltd | Chemical compounds |
| PT83094B (pt) * | 1985-07-30 | 1993-07-30 | Glaxo Group Ltd | Dispositivos proprios para a administracao de medicamentos a pacientes |
| EP0220054A3 (en) | 1985-10-16 | 1987-12-02 | Glaxo Group Limited | Ethanolamine derivatives |
| GB8718940D0 (en) | 1987-08-11 | 1987-09-16 | Glaxo Group Ltd | Chemical compounds |
| GB2230523A (en) | 1989-04-14 | 1990-10-24 | Glaxo Group Ltd | 1-(3-Bromoisoxazol-5-yl)-2-aminoethanol derivatives |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| EP0947498B1 (en) | 1996-12-02 | 2004-09-15 | Chisso Corporation | Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for preparing the same |
| GB9700226D0 (en) * | 1997-01-08 | 1997-02-26 | Glaxo Group Ltd | Inhalation device |
| WO1999016766A1 (en) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Benzodioxole derivatives |
| AU3328499A (en) | 1998-03-14 | 1999-10-11 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phthalazinone pde iii/iv inhibitors |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| CZ302882B6 (cs) | 1999-08-21 | 2012-01-04 | Nycomed Gmbh | Farmaceutický prostredek |
| US6632666B2 (en) * | 2000-01-14 | 2003-10-14 | Biolife Solutions, Inc. | Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| RU2312854C2 (ru) * | 2001-09-14 | 2007-12-20 | Глаксо Груп Лимитед | Производные фенэтаноламина для лечения респираторных заболеваний |
-
2003
- 2003-12-17 GB GBGB0329182.0A patent/GB0329182D0/en not_active Ceased
-
2004
- 2004-12-15 US US10/595,997 patent/US7294650B2/en not_active Expired - Fee Related
- 2004-12-15 EP EP04803990A patent/EP1730133A1/en not_active Withdrawn
- 2004-12-15 WO PCT/EP2004/014381 patent/WO2005058867A1/en not_active Ceased
- 2004-12-15 JP JP2006544348A patent/JP2007514691A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007514691A5 (enExample) | ||
| JP2006504766A5 (enExample) | ||
| JP7431900B2 (ja) | （ｓ）－３－（４－（（４－（モルホリノメチル）ベンジル）オキシ）－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオンの塩及び固体形態、並びにそれらを含有する組成物及び使用方法 | |
| JP2007509103A5 (enExample) | ||
| JP2020169171A5 (enExample) | ||
| JP2005533868A5 (enExample) | ||
| JP2004526720A5 (enExample) | ||
| RU2005111975A (ru) | Производные фенэтаноламина для лечения респираторных заболеваний | |
| JP2005519083A5 (enExample) | ||
| JP2004538259A5 (enExample) | ||
| JP2007509852A5 (enExample) | ||
| JP2004524308A5 (enExample) | ||
| JP2006506373A5 (enExample) | ||
| JP2019518050A5 (enExample) | ||
| JP2006503888A5 (enExample) | ||
| JP2005534635A5 (enExample) | ||
| JP2010100633A (ja) | イロペリドン代謝産物の光学異性体 | |
| KR20110086731A (ko) | 치환된 다이옥소피페리디닐 프탈이미드 유도체 | |
| JP2011509309A5 (enExample) | ||
| JP2018513832A5 (enExample) | ||
| JP2005514457A5 (enExample) | ||
| JP7419503B2 (ja) | 置換フェニル又はピリジニル部分を有するｓｅｒｄ三環化合物の製造方法 | |
| RU2011133128A (ru) | Противоопухолевые соединения дигидропиран-2-она | |
| JP2011509302A5 (enExample) | ||
| JP2009533417A5 (enExample) |